Amgen Inc (AMGN)
$435.64 -$1.94 (-0.44%) 4:40 AM 11/22/2026
NASDAQ | $USD | Drug Manufacturers - GeneralStock Data
-
Market Cap
$236.35B -
Day's Range
$434.51 - $445.49 -
Volume
2,791,503 -
52 Week Low / High
$312.39 - $483.99 -
PE Ratio
25.33x -
PEG Ratio
- -
Dividend Frequency
quarterly
Analyst ratings: Buy 12, Hold 17, Sell 5.
Company News
-
Stock Market Today: Nasdaq Sells Off As Anthropic Plunges 10% After IPO (Live Coverage) — Nov 20, 2026
Stock Market Today: Tech futures tumble Friday after Thursday's market sell-off. Anthropic stock plunges after its IPO....
-
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know — Nov 20, 2026
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this world's largest biotech drugmaker have returned -1.9%, compar...
-
What SPDR Dow Jones Industrial Avg ETF (DIA) Bought: Goldman Leads on Nov. 18 — Nov 20, 2026
This article first appeared on GuruFocus. Spdr Dow Jones Industrial Average ETF Trust (DIA) was the single fund that moved the most in Wednesday's session, with ETF activity totaling $536.8 million in gross trades, all of it on the buy side. DIA added to 29 positions and trimmed none, for ...
-
Insmed may be worth $170 to $210 a share in takeover, analyst — Nov 19, 2026
[Insmed headquarters in Bridgewater Township, NJ, USA.] JHVEPhoto Insmed (INSM [https://seekingalpha.com/symbol/INSM]) may be worth $170-$210 a share in a takeover after a report that Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) is weighing a purchase [https://seekingalpha.com/news/4...
-
Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says — Nov 19, 2026
Viridian Therapeutics' (VRDN) Lumvoa is emerging as a "credible" competitor to Amgen's (AMGN) Tepezz Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT Newswires articles Stock picks Expert picks from Motley ...
-
Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials — Nov 19, 2026
Amgen (NasdaqGS:AMGN) has advanced its obesity drug candidate MariTide into Phase 3 clinical trials, targeting the growing anti-obesity treatment market. The firm is positioning MariTide to compete with existing anti-obesity therapies from established players such as Eli Lilly and Novo Nor...
-
What SPDR Dow Jones Industrial Avg ETF (DIA) Bought: Goldman Sachs Leads on Nov. 17 — Nov 19, 2026
This article first appeared on GuruFocus. SPDR Dow Jones Industrial Average ETF Trust (DIA) extended its run of broad additions, lifting all 30 of its positions in Tuesday's session. The fund's ETF activity totaled $481.4 million in gross trades, all of it net buying, against $43.97 billio...
-
Biggest Dow Jones Loser Nike Keeps Sinking After Investor Day. Here's Why. — Nov 18, 2026
Sneaker giant Nike failed to reassure investors about its turnaround strategy after extended earnings slump....
-
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16 — Nov 18, 2026
This article first appeared on GuruFocus. iShares Biotechnology ETF (IBB) recorded net buying of $176.7 million in Monday's session, with gross ETF activity of the same amount across its portfolio. IBB increased 233 positions and decreased none, with no new positions or exits reported. The...
-
Spdr Dow Jones (DIA) Sells Goldman Sachs and Caterpillar on Nov. 16 — Nov 18, 2026
This article first appeared on GuruFocus. Spdr Dow Jones Industrial Average ETF Trust (DIA) reported $721.3 million in ETF activity on Monday, all of it selling. The fund, with $45.43 billion in assets, increased no positions and decreased all 30 of its holdings, leaving net bought at -$72...
Portfolio
Comprised of 1 portfolios



